Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease

touchEXPERT FOCUS for touchONCOLOGY

Listen to a series of short interviews with three leading experts discussing the application of immunotherapy in triple-negative breast cancer (TNBC). The experts explore the latest data and guideline recommendations for immunotherapy in early-stage and metastatic TNBC, and how to maximize treatment benefits. 

The experts:

• Prof. Sherko Kümmel – Kliniken Essen-Mitte, Essen, Germany
• Prof. Rebecca Dent – National Cancer Center Singapore, Singapore
• Prof. Peter Schmid – Barts Cancer Institute, London, UK

This touchPODCAST is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

https://touchoncologyime.org/management-of-tnbc-with-immunotherapy/